Skip to content
10-Q

Quarterly Report

RECURSION PHARMACEUTICALS, INC. RXRX

0001601830-25-000127

← back to feed
Filed
Aug 5, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q2 2025 · Jun 30, 2025 417.36M sh
Shares Diluted Q2 2025 · Jun 30, 2025 410.27M sh
Shares Diluted Q2 2025 · Jun 30, 2024 242.2M sh
Shares Diluted Q2 2025 · Jun 30, 2024 239.11M sh
Capex Q2 2025 · Jun 30, 2025 $4.98M
Capex Q2 2025 · Jun 30, 2024 $7.84M
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$208.38M
Operating Cash Flow Q2 2025 · Jun 30, 2024 −$184.52M
Cash And Equivalents Q2 2025 · Jun 30, 2025 $525.11M
Cash And Equivalents Q2 2025 · Dec 31, 2024 $594.35M
Stockholders Equity Q2 2025 · Jun 30, 2025 $919.15M
Stockholders Equity Q2 2025 · Mar 31, 2025 $933.95M
Stockholders Equity Q2 2025 · Dec 31, 2024 $1.03B
Stockholders Equity Q2 2025 · Jun 30, 2024 $584.45M
Stockholders Equity Q2 2025 · Mar 31, 2024 $401.15M
Stockholders Equity Q2 2025 · Dec 31, 2023 $463.44M
Current Liabilities Q2 2025 · Jun 30, 2025 $164.03M
Current Liabilities Q2 2025 · Dec 31, 2024 $187.47M
Total Liabilities Q2 2025 · Jun 30, 2025 $383.21M
Total Liabilities Q2 2025 · Dec 31, 2024 $413.82M
Current Assets Q2 2025 · Jun 30, 2025 $587.16M
Current Assets Q2 2025 · Dec 31, 2024 $714.27M
Total Assets Q2 2025 · Jun 30, 2025 $1.3B
Total Assets Q2 2025 · Dec 31, 2024 $1.45B
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.41
Eps Diluted Q2 2025 · Jun 30, 2025 −$0.91
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.40
Eps Diluted Q2 2025 · Jun 30, 2024 −$0.79
Eps Basic Q2 2025 · Jun 30, 2025 −$0.41
Eps Basic Q2 2025 · Jun 30, 2025 −$0.91
Eps Basic Q2 2025 · Jun 30, 2024 −$0.40
Eps Basic Q2 2025 · Jun 30, 2024 −$0.79
Sga Expense Q2 2025 · Jun 30, 2025 $46.65M
Sga Expense Q2 2025 · Jun 30, 2025 $101.3M
Sga Expense Q2 2025 · Jun 30, 2024 $31.83M
Sga Expense Q2 2025 · Jun 30, 2024 $63.24M
Rd Expense Q2 2025 · Jun 30, 2025 $128.64M
Rd Expense Q2 2025 · Jun 30, 2025 $258.27M
Rd Expense Q2 2025 · Jun 30, 2024 $73.93M
Rd Expense Q2 2025 · Jun 30, 2024 $141.49M
Net Income Q2 2025 · Jun 30, 2025 −$171.9M
Net Income Q2 2025 · Jun 30, 2025 −$374.38M
Net Income Q2 2025 · Jun 30, 2024 −$97.54M
Net Income Q2 2025 · Jun 30, 2024 −$188.91M
Operating Income Q2 2025 · Jun 30, 2025 −$176.23M
Operating Income Q2 2025 · Jun 30, 2025 −$367.6M
Operating Income Q2 2025 · Jun 30, 2024 −$100.54M
Operating Income Q2 2025 · Jun 30, 2024 −$196.88M
Cost Of Revenue Q2 2025 · Jun 30, 2025 $20.16M
Cost Of Revenue Q2 2025 · Jun 30, 2025 $41.99M
Cost Of Revenue Q2 2025 · Jun 30, 2024 $9.2M
Cost Of Revenue Q2 2025 · Jun 30, 2024 $20.37M
Revenue Q2 2025 · Jun 30, 2025 $19.22M
Revenue Q2 2025 · Jun 30, 2025 $33.97M
Revenue Q2 2025 · Jun 30, 2024 $14.42M
Revenue Q2 2025 · Jun 30, 2024 $28.21M